Kevin N. Heller - 21 Mar 2022 Form 4 Insider Report for Jasper Therapeutics, Inc. (JSPR)

Role
Executive Vice President, Research and Development
Signature
/s/ Jeet Mahal, as Attorney-in-Fact
Issuer symbol
JSPR
Transactions as of
21 Mar 2022
Net transactions value
$0
Form type
4
Filing time
23 Mar 2022, 18:04:14 UTC
Previous filing
01 Oct 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JSPR Stock Option (right to buy) Award $0 +7,500 $0.000000 7,500 21 Mar 2022 Voting Common Stock 7,500 $3.54 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4th of the shares subject to the option shall vest on December 7, 2022, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Remarks:

Executive Vice President, Research and Development